Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.57 |
| ▸ | CCND1 | P24385 | 17/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.57 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.57 |
| ▸ | CDK4 | P11802 | 6/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.57 |
| ▸ | CDK9 | P50750 | 2/20 | 0.57 |
| ▸ | CCND3 | P30281 | 2/20 | 0.57 |
| ▸ | PRKDC | P78527 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.47 |
| ▸ | CCND2 | P30279 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122980 | 1.00 | CDK2 (0.57) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL25122544 | 0.93 | CDK2 (0.59) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27358069 | 0.92 | CDK2 (0.58) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27358813 | 0.91 | CDK2 (0.55) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27358622 | 0.91 | CDK2 (0.53) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27357491 | 0.90 | CDK2 (0.54) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL25122543 | 0.90 | CDK2 (0.54) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27358731 | 0.90 | CDK2 (0.54) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL29991292 | 0.90 | CDK2 (0.60) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27166378 | 0.90 | CDK2 (0.60) | CDK2CCND1CCNE1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | CDK2 1/4885CCND1 49/4885CCNE1 36/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CDK2 1/4885CCND1 49/4885CCNE1 36/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CDK2 1/4885CCND1 49/4885CCNE1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.